Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases
Authors:
- J.M. ClasseJCJ.M. Classe
- I. JaffreIJI. Jaffre
- J.S. FrenelJFJ.S. Frenel
- V. BordesVBV. Bordes
- M. DejodeMDM. Dejode
- F. DravetFDF. Dravet
- G. FerronGFG. Ferron
- F. MarchalFMF. Marchal
- D. Berton RigaudDRD. Berton Rigaud
- D. LoussouarnDLD. Loussouarn
- L. CampionL. Campion
- 1 November 2011
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 37 (11) , 971-977
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Cytoreductive surgery for recurrent ovarian cancer: A meta-analysisGynecologic Oncology, 2009
- Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinomaCancer, 2006
- A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patientsAnnals of Oncology, 2006
- 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Annals of Oncology, 2005
- Cancer of the OvaryNew England Journal of Medicine, 2004
- Tertiary cytoreduction in patients with recurrent ovarian carcinomaGynecologic Oncology, 2004
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003
- “Recurrence within 6 Months of Platinum Therapy”: An Adequate Definition of “Platinum-Refractory” Ovarian Cancer?Gynecologic Oncology, 1998
- Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination RegimensGynecologic Oncology, 1998